Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841669 | 0.88 | PDE4B (0.57) | PDE4BPDE3APDE4DSLC6A2PDE4A | |
| SCHEMBL2845710 | 0.87 | PDE4B (0.41) | PDE4BPDE3APDE4DSLC6A2PDE4A | |
| SCHEMBL2842070 | 0.84 | PDE4B (0.42) | PDE4BPDE3APDE4DSLC6A2PDE4A | |
| SCHEMBL2851371 | 0.79 | PDE4B (0.70) | PDE4BPDE3ACNR2 | |
| SCHEMBL2845152 | 0.77 | PDE4B (0.62) | PDE4BPDE3APDE4DPDE4APDE4C | |
| SCHEMBL3126420 | 0.77 | PDE4B (0.44) | PDE4BPDE3ACNR2PDE4DSLC6A2 | |
| SCHEMBL2850758 | 0.76 | PDE4B (0.58) | PDE4BPDE3APDE4DSLC6A2 | |
| SCHEMBL2852198 | 0.76 | PDE4B (0.68) | PDE4BPDE3APDE4DSLC6A2 | |
| SCHEMBL2845291 | 0.75 | PDE4B (0.59) | PDE4BPDE3APDE4DSLC6A2 | |
| SCHEMBL3111457 | 0.75 | PDE4A (0.44) | PDE4BCNR2PDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2168960-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE3B, PDE2A | PDE4B 6/4885PDE3A 1/4885CNR2 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.